Riskpilot← Back to searchSign inGet full accessPHARMAORIGIN ApS
APSActiveCVR 29178291Amaliegade 10Other human health activities n.e.c. · NACE 8699Est. 2005— employees
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK 94K
+8% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 94K | +8% |
| Total assets | DKK 1,4M | +7% |
| Equity | DKK 1,4M | +7% |
| Employees | — | — |
Legal name
PHARMAORIGIN ApS
CVR number
29178291
Legal form
Anpartsselskab
NACE code
8699 · Other human health activities n.e.c.
Founded
14. november 2005
Share capital
DKK 245.834
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at udvikle lægemidler samt dermed beslægtede aktiviteter.
Address
Amaliegade 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -144 | -632 | -313 | -179 | -1.713 | 4.296 | -67 | -24 | -30 | -5 | 0 | 0 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -4.336 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -144 | -632 | -313 | -179 | -1.713 | -40 | -67 | -24 | -30 | -5 | 0 | 0 | 0 |
| Net financials | -174 | -305 | -441 | 0 | 0 | -44 | -44 | 43 | 43 | 45 | 47 | 87 | 94 |
| Profit before tax | -99 | -1.037 | -754 | -179 | -1.713 | -4.332 | -23 | 18 | 13 | 40 | 47 | 87 | 94 |
| Tax | 50 | -0 | -196 | -44 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -149 | -938 | -558 | -135 | -1.713 | -4.332 | -23 | 18 | 13 | 40 | 47 | 87 | 94 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.944 | 5.254 | 5.584 | 6.957 | 5.432 | 1.100 | 1.077 | 1.095 | 1.118 | 1.159 | 1.206 | 1.283 | 1.378 |
| Equity | 806 | -132 | 4.310 | 4.175 | 5.432 | 1.100 | 1.077 | 1.095 | 1.108 | 1.149 | 1.196 | 1.283 | 1.378 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4.138 | 5.386 | 1.274 | 2.781 | 0 | 0 | 0 | 0 | 10 | 10 | 10 | 0 | 0 |
| Total debt | 4.138 | 5.386 | 1.274 | 2.781 | 0 | 0 | 0 | 0 | 10 | 10 | 10 | 0 | 0 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20122024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20122024
Return on equity
6.8%
This company
18.4%
Market median
-63% vs market
20122024
Net profit margin
9400000.0%
This company
8.1%
Market median
+116049283% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KF Chief Executive Officer | Chief Executive Officer | 2006 | — | — |
RN Management | Management | 2016 | — | — |
TG Management | Management | 2005 | — | — |
DL Management | Management | 2017 | — | — |
HL Chief Executive Officer | Chief Executive Officer | 2011 | — | — |
PA Management | Management | 2005 | — | — |
SB Management | Management | 2015 | — | — |
LH Management | Management | 2005 | — | — |
KA Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2008 | — | — | |
| Chairman | 2007 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Savara ApS | Company | 100.0% | 100.0% | 2016 |
Serenova A/S | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Savara ApS
PHARMAORIGIN ApS Board members of PHARMAORIGIN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kaare Fiala | Chief Executive Officer | 0 companies |
| Robert Norman Neville | Management | 0 companies |
| Tom Glæsner Larsen | Management | 0 companies |
| David Lee Lowrance | Management | 0 companies |
| Henrik Lasse Lindblad | Chief Executive Officer | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Søren Bech Justesen | Management | 0 companies |
| Lars Heslet | Management | 0 companies |
| Kim Arvid Nielsen | Chief Executive Officer | 0 companies |
| Leif Helth Jensen | Board of Directors | 0 companies |
| Peter Høngård Andersen | Board of Directors | 0 companies |
| Eric Jean Marie Leire | Chairman | 0 companies |